EA201101035A1 - Новый конъюгат гранулоцитарного колониестимулирующего фактора (г-ксф) с полиэтиленгликолем - Google Patents

Новый конъюгат гранулоцитарного колониестимулирующего фактора (г-ксф) с полиэтиленгликолем

Info

Publication number
EA201101035A1
EA201101035A1 EA201101035A EA201101035A EA201101035A1 EA 201101035 A1 EA201101035 A1 EA 201101035A1 EA 201101035 A EA201101035 A EA 201101035A EA 201101035 A EA201101035 A EA 201101035A EA 201101035 A1 EA201101035 A1 EA 201101035A1
Authority
EA
Eurasian Patent Office
Prior art keywords
csf
granulocitar
colonius
polyethylene glycol
conjugate
Prior art date
Application number
EA201101035A
Other languages
English (en)
Other versions
EA019043B1 (ru
Inventor
Татьяна Вениаминовна ЧЕРНОВСКАЯ
Лев Александрович Денисов
Дмитрий Валентинович МОРОЗОВ
Елена Георгиевна Руденко
Елена Леонидовна Морозова
Original Assignee
Закрытое Акционерное Общество "Биокад"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45567857&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201101035(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Закрытое Акционерное Общество "Биокад" filed Critical Закрытое Акционерное Общество "Биокад"
Publication of EA201101035A1 publication Critical patent/EA201101035A1/ru
Publication of EA019043B1 publication Critical patent/EA019043B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

Изобретение относится к фармацевтике и медицине, а именно к новым физиологически активным конъюгатам гранулоцитарного колониестимулирующего фактора (Г-КСФ) общей формулы:где n - целые значения от 227 до 1 000; m представляет собой целое число ≥4; NαH-Г-КСФ - представляет собой гранулоцитарный колониестимулирующий фактор. Также изобретение относится к лекарственным средствам, содержащим заявляемый коньюгат формулы (I), фармацевтическим композициям, применению коньюгата формулы (I) для получения лекарственного средства и лекарственным средствам, обладающим активностью гранулоцитарного колониестимулирующего фактора, способу профилактики и/или лечения нейтропении, контейнеру, включающему фармацевтическую композицию или лекарственное средство, и набору.
EA201101035A 2010-08-13 2011-08-01 Новый конъюгат гранулоцитарного колониестимулирующего фактора (г-ксф) с полиэтиленгликолем EA019043B1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2010133875/10A RU2446173C1 (ru) 2010-08-13 2010-08-13 Новый функционально активный, высокоочищенный стабильный конъюгат гранулоцитарного колониестимулирующего фактора (г-ксф) с полиэтиленгликолем с пролонгированным биологическим действием, пригодный для медицинского применения, и иммунобиологическое средство на его основе

Publications (2)

Publication Number Publication Date
EA201101035A1 true EA201101035A1 (ru) 2012-02-28
EA019043B1 EA019043B1 (ru) 2013-12-30

Family

ID=45567857

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201101035A EA019043B1 (ru) 2010-08-13 2011-08-01 Новый конъюгат гранулоцитарного колониестимулирующего фактора (г-ксф) с полиэтиленгликолем

Country Status (17)

Country Link
KR (1) KR101549457B1 (ru)
CN (1) CN103140499B (ru)
CL (1) CL2013000400A1 (ru)
CO (1) CO6670557A2 (ru)
CR (1) CR20130020A (ru)
CU (1) CU24139B1 (ru)
DO (1) DOP2013000003A (ru)
EA (1) EA019043B1 (ru)
EC (1) ECSP13012399A (ru)
MA (1) MA34525B1 (ru)
MY (1) MY160732A (ru)
NI (1) NI201300007A (ru)
PE (1) PE20131085A1 (ru)
RS (1) RS20130094A1 (ru)
RU (1) RU2446173C1 (ru)
SG (1) SG187572A1 (ru)
WO (1) WO2012021088A1 (ru)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10286039B2 (en) 2014-02-18 2019-05-14 Children's Hospital Los Angeles Compositions and methods for treating neutropenia
US11116738B2 (en) 2012-06-07 2021-09-14 Children's Hospital Los Angeles Methods for treating neutropenia using retinoid agonists

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012110057A1 (en) 2011-02-15 2012-08-23 Chemisches Institut Schaefer Ag Cefuroxime safety kit
CN103908427B (zh) * 2013-01-05 2014-12-17 石药集团百克(山东)生物制药有限公司 一种聚乙二醇修饰的rhG-CSF注射液及其制备方法
RU2535002C2 (ru) * 2013-04-04 2014-12-10 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт фармакологии" Сибирского отделения Российской академии медицинских наук Средство коррекции отдаленных последствий нарушений сперматогенеза, вызванных цитостатическим воздействием
PE20170769A1 (es) 2014-07-14 2017-07-04 Gennova Biopharmaceuticals Ltd Procedimiento novedoso para la purificacion de rhu-gcsf
IL247369B (en) * 2016-08-18 2018-08-30 B G Negev Tech And Applications Ltd Polypeptides derived from CSF-m and their uses
KR102020995B1 (ko) * 2017-10-30 2019-09-16 한국코러스 주식회사 콜로니자극인자와 폴리올이 접합된 접합물을 고수율로 제조하는 방법
BR112022018501A2 (pt) * 2020-03-17 2022-10-25 Drugrecure Aps Formulação líquida de gm-csf para inalação

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990006952A1 (en) * 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
US5252714A (en) * 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
KR20040083268A (ko) * 2003-03-21 2004-10-01 한미약품 주식회사 안정성이 증가된 인간 과립구 콜로니 자극인자 융합체 및이의 제조방법
RU2278870C2 (ru) * 2004-08-30 2006-06-27 Закрытое Акционерное Общество "Биокад" Способ получения, выделения, очистки и стабилизации рекомбинантного гранулоцитарного колониестимулирующего фактора человека, пригодного для медицинского применения, и иммунобиологическое средство на его основе
CN101400363B (zh) * 2006-01-18 2012-08-29 昌达生物科技公司 具有增强的稳定性的药物组合物
US8840882B2 (en) * 2006-06-23 2014-09-23 Quintessence Biosciences, Inc. Modified ribonucleases

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11116738B2 (en) 2012-06-07 2021-09-14 Children's Hospital Los Angeles Methods for treating neutropenia using retinoid agonists
US10286039B2 (en) 2014-02-18 2019-05-14 Children's Hospital Los Angeles Compositions and methods for treating neutropenia

Also Published As

Publication number Publication date
KR101549457B1 (ko) 2015-09-02
ECSP13012399A (es) 2013-05-31
EA019043B1 (ru) 2013-12-30
KR20130043167A (ko) 2013-04-29
WO2012021088A1 (en) 2012-02-16
CR20130020A (es) 2013-02-20
RU2446173C1 (ru) 2012-03-27
RS20130094A1 (en) 2013-08-30
DOP2013000003A (es) 2013-07-31
CN103140499B (zh) 2014-12-17
PE20131085A1 (es) 2013-10-10
SG187572A1 (en) 2013-03-28
NI201300007A (es) 2014-05-26
CO6670557A2 (es) 2013-05-15
CU20130012A7 (es) 2013-04-19
MA34525B1 (fr) 2013-09-02
CL2013000400A1 (es) 2013-07-26
CN103140499A (zh) 2013-06-05
CU24139B1 (es) 2015-12-23
MY160732A (en) 2017-03-15

Similar Documents

Publication Publication Date Title
EA201101035A1 (ru) Новый конъюгат гранулоцитарного колониестимулирующего фактора (г-ксф) с полиэтиленгликолем
BR112013003045A2 (pt) composto e composição farmacêutica e respectivos usos, recipiente estéril e método para preparar composição farmacêutica para administração
CY1119616T1 (el) Συζευγματα ανθρωπινου αντισωματος-φαρμακου κατα του ιστικου παραγοντα
MX2012007410A (es) Compuestos antivirales novedosos.
NZ605887A (en) Pharmaceutical dosage form comprising 6’-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4’,9’-dihydro-3’h-spiro[cyclohexane-1,1’-pyrano[3,4,b]indol]-4-amine for the treatment of neuropathic pain
MX2015003653A (es) Derivados de amida del acido benzoimidazol-carboxilico como moduladores del receptor apj.
EA201171376A1 (ru) Производные тиено[2,3-b]пиридина в качестве ингибиторов репликации вируса
PH12014502524B1 (en) Carboxylic acid compounds
MX2011013150A (es) Composicion farmaceutica para uso en oftalmologia medica y veterinaria.
CY1113269T1 (el) Παραγωγα ινδαζολυλ αμιδιου για τη θεραπευτικη αγωγη διαταραχων διαμεσολαβουμενων υπο υποδοχεα γλυκοκορτικοειδων
MX2014009757A (es) Derivados de isoindolina, composiciones farmaceuticas que los contienen y su uso en terapia.
FR2900404B1 (fr) Nouveaux derives d'imidazoles, leur preparation et leur utilisation en tant que medicament
TW200731975A (en) Novel combinations of medicaments for the treatment of respiratory diseases
EA201390984A1 (ru) Гетероциклические соединения, подходящие для лечения дислипидемии
MY168784A (en) The new stable polyethylene glycol conjugate of interferon alpha,represented by one positional isomer
EA200501870A1 (ru) Новые производные имидазолов, способ их получения и их применение в качестве лекарственного средства
UA107349C2 (en) Imidazolidine-2,4-dione derivatives, and use thereof as a cancer drug
CY1115600T1 (el) Πιπεραζινες ως ανθελονοσιακοι παραγοντες
TW200740440A (en) Novel combinations of medicaments for the treatment of respiratory diseases containing long-acting beta-agonists and at least one additional active ingredient
CR20220620A (es) Composición farmacéutica acuosa de levilimab y su uso
BR112012020415A2 (pt) composição farmacêutica para a prevenção ou tratamento da osteoartrite
EA202191014A1 (ru) Производные 4-пиразин-2-илметил-морфолина и их применение в качестве лекарственного средства
WO2015027669A3 (zh) 苯基取代化合物及其药物组合物和应用
BR0209138A (pt) Utilização de derivados de piridoindolona para a preparação de medicamentos
RU2012111354A (ru) Новые кристаллические гидраты фторгликозидов, содержащие их фармацевтические препараты и их использование

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG RU